Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Shionogi to Realign Japan Sales Teams, Heed Regional Demands
September 10, 2014
- Zeria’s PMS Treatment Prefemin Now on Sale as “Drug Requiring Guidance”
September 10, 2014
- Janssen Discloses 2013 Payments of 8.3 Billion Yen to Healthcare Professionals
September 10, 2014
- Otsuka to Launch Deltyba on September 26; Launch Delayed in Anticipation of Revised TB Treatment Guidelines
September 10, 2014
- Medical & Biological Lab Seeking Partner for Dengue Fever Drug Development
September 9, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
September 9, 2014
- Ethical Drug Sales Down 3.0% in July: Crecon Report
September 9, 2014
- Ono, Bristol-Myers Sue Merck over Anti-PD-1 Antibody Patent
September 9, 2014
- Chugai Launches ALK Inhibitor Alecensa
September 9, 2014
- Pfizer Japan, Astellas to Terminate Copromotion Deal for Caduet in March Next Year
September 9, 2014
- MSD Sales Structure Now Tailored to Local Healthcare Needs: Pres.
September 8, 2014
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Meiji Seika Pharma, Takeda to Copromote Insomnia Treatment Rozerem from October
September 8, 2014
- Bayer Yakuhin Files Eylea for Macular Edema Secondary to Branch Retinal Vein Occlusion
September 8, 2014
- Takeda Files Leuplin 6-Month Depot Formulation in Japan
September 8, 2014
- MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing
September 5, 2014
- Januvia Retains Its No. 1 Spot in the GP Market in July: Anterio’s “Mind Share” Ranking
September 5, 2014
- Takeda Transfers All Shares of Its Subsidiary Nippon-Rinshosha to Medical Tribune
September 5, 2014
- Sanofi Launches Prostate Cancer Agent Jevtana
September 5, 2014
- Kaketsuken Completes New Manufacturing Plant for Increasing Production Capacity of Hepatitis B Vaccine
September 5, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…